TriSalus Life Sciences, Inc.
TLSIW- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
In the last 90 days, TriSalus Life Sciences, Inc. insiders filed 1 open-market purchase and 3 sales; 5 institutions reported holding it in 13F filings for Q2 2026, worth $798.0K in total; no superinvestor holds it.
Other share classesTLSI
Key figures
- Market capClose on Nov 17, 2026
- $141.6M
- Insider buysLast 90 days, $112.0K in total
- 1
- Insider sellsLast 90 days, $4.11K in total
- 3
- 13F holdersQ2 2026, −2 vs. previous quarter
- 5
- 13F valueReported value at the end of Q2 2026
- $798.0K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $45.2M
- +53.4% year over year
- Net income, FY2025
- -$39.2M
- No comparable prior period
- Free cash flow, FY2025
- -$18.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $12.9M
- +11.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $39.2M (86.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 16.2K
- Shares sold short
- Change
- +5.33K
- +48.9% vs. previous
- Days to cover
- 12.42
- At average daily volume
Superinvestors holding TLSIW, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TLSIW at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by TriSalus Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)8:16 AM ET | Nov 12 | 4 days | Wahlstrom MatsDirector | PPurchase | +50.0K | $2.24 | +$112.0K | +33.9%197.6K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Cox Bryan F.Chief of Research | SSale | −296 | $4.39 | −$1.30K | −0.2%162.8K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Marshak RichardChief Commercial Officer | SSale | −325 | $4.39 | −$1.43K | −0.3%128.0K after | |
| Oct 7, 2026 (view filing)4:02 PM ET | Oct 5 | 2 days | Stevens JenniferChief Regulatory Officer | SSale | −316 | $4.39 | −$1.39K | −0.3%123.8K after | |
| May 19, 2026 (view filing) | May 15 | 4 days | Marshak RichardChief Commercial Officer | SSale | −543 | $2.67 | −$1.45K | −0.4%125.1K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +410.0K | $2.50 | +$1.02M | +49.4%1.24M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +200.0K | $2.50 | +$500.0K | +100.2%399.7K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Szela Mary TCEO and President | PPurchase | +39.7K | $2.59 | +$102.8K | +3.9%1.07M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Patience DavidChief Financial Officer | PPurchase | +7.10K | $2.43 | +$17.3K | +2.6%275.8K after |
Top 10 13F holders, Q2 2026
See all 5 holdersThe largest institutional positions in TriSalus Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cerity Partners LLC | 827,590 | $662.1K | 0.00% | 00.0% | Unchanged |
| Aristeia Capital LLC | 74,826 | $56.9K | 0.00% | +46,210+161.5% | Added |
| Vestcor Inc | 70,832 | $54.0K | 0.00% | 00.0% | Unchanged |
| Fort Baker Capital Management LP | 26,374 | $21.1K | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 5,170 | $3.93K | 0.00% | 00.0% | Unchanged |